Find an Article

Filter articles

Applied Filters

Showing 81 to 90 of 136 results

Stemming the tide of rejections

Mexico16-06-2015Jasmin Maqueda

Mexican patent examiners usually reject patents directed to human embryonic stem cells, but applications filed after 2008 may have a greater chance of being approved, as Jasmin Maqueda of Becerril, Coca & Becerril describes.

Gilead: Treating the seven million


Pharma company Gilead has been in the headlines since it launched its blockbuster drug Sovaldi with a hefty price tag. Less reported, however, are its numerous patent licensing deals that ensure wider access to medicines in the developing world. LSIPR spoke to Christina Carlson, senior counsel at Gilead Sciences, to find out more.

New players on the patent chess board

US14-05-2015Marc Cavan and Phillip Kurs

The ability of third parties to participate in patent challenges has led to new dynamics, including the possibility of parties profiting from movements in stock price and the prospect of patent oppositions by not-for-profit proxies, as Marc Cavan and Phillip Kurs of law firm Ropes & Gray describe.

UPC: keeping a weather eye

EU, US23-04-2015Paul England and Simon Cohen

In the second instalment of a regular column on the unitary patent and Unified Patent Court by law firm Taylor Wessing, Paul England and Simon Cohen discuss how watching the new system will also mean monitoring the old one.

Market exclusivity: Lucky orphans

EU20-03-2015Trevor Cook

Orphan medicinal products in Europe benefit from a range of incentives, but the greatest of these is the promise of receiving a ten-year period of true market exclusivity, says Trevor Cook of Wilmer Cutler Pickering Hale and Dorr.

Data exclusivity in India: a new tool for innovators?


As India appears to forge closer trade relations with the US, will the country introduce a data exclusivity legal provision and what impact would this have? LSIPR investigates.

India focus: Better protection for big pharma?


The battle between pharmaceutical and generics companies in India is once again in the spotlight, with a decision pending on another compulsory licence. The players this time are Novartis and Cipla, with the former already having drawn first blood. LSIPR investigates.

Co-pending applications: Collision course

EU03-03-2015Jane Wainwright

Previously for LSIPR, Jane Wainwright of Potter Clarkson investigated the emergence of self-colliding patent filings in Europe and their relevance to the life sciences. As the European Patent Office begins to review this issue at the highest level, she revisits the concept and why it is now being reconsidered.

Generics in Canada: The race for market exclusivity

Canada03-03-2015Gunars Gaikis

Section 8 of Canada’s Patented Medicines (Notice of Compliance) Regulations is a unique provision under which an innovator can be liable for a generic’s losses that result from a delay in coming to market, as Gunars Gaikis explains

Momentum building for the UPC

EU, France, Germany, UK19-02-2015Paul England

The unitary patent and Unified Patent Court will have wide-ranging implications for life sciences companies. In the first of what will be a regular column on the topics by law firm Taylor Wessing, Paul England explores current developments on issues such as costs and judges.

Showing 81 to 90 of 136 results